At RIBOPRO, we are on a mission to revolutionize medicine, through mRNA.
This mission can only be achieved by collaborating with innovators around the world. And so, we are working hard every day to be the best partner in mRNA.
Our company
Dream ahead
Our vision
In 20 years from now, 90% of all new medicines will be RNA-based, because of the radically enhanced safety and efficacy of this class of therapeutics. With the power of mRNA, chronic illnesses will be curable, deadly diseases survivable, and rare disease treatment affordable.
Beyond medicine, (m)RNA will contribute to answers to the most important ecological, health, and food challenges we face today. Together, we can make this a reality, if we dare to follow our dreams.
Motivated
Our mission
It is our mission to revolutionize medicine by being the most innovative and supportive technology partner for RNA-therapy pioneers.
Together, we will create scientific breakthroughs, bring novel, better medicines to the patient, or address other societal challenges, such as the environment.
About us
Founded by scientists, our company is built on more than a decade of hands-on experience with mRNA synthesis and formulation. And we are happy to share our knowledge and expertise.
We started RIBOPRO from a desire to help innovators around the world bring new medicines to the patient. We believed access to high-quality material and to technologies that affect the performance of the drug were critical to that mission. Thus, through in-house research, we developed both the manufacturing processes for high quality mRNA and LNPs, and developed novel technologies to boost the performance of the mRNA/gain control over the delivery. These technologies not only provide better outcomes, but also provide freedom to operate in an otherwise competitive marketplace.
We go beyond. Beyond the expected, by challenging the status quo. By thinking ahead and working harder we achieve more. For us going above and beyond is our daily routine. We do so because we have a clear vision of the rewards when we do.
Our history
Our team
a dedicated team of highly skilled professionals
Open popup about Sander van Asbeck
Sander van Asbeck
CEO & co-founder- 10+ yrs of experience
- Technology & vision
More information
CEO & co-founder
Sander van Asbeck
Sander is a molecular biology expert, founder of Mercurna (targeted mRNA therapeutics developer) and founder & CEO of RiboPro, a premier CDMO and technology provider specialized in mRNA and mRNA delivery. As CEO he enjoys working together with all stakeholders to find the best scientific, clinical and/or commercial solutions, to advance his dream of a medical revolution through (m)RNA.
Sander previously worked on:
- mRNA-based drug-development @ Mercurna
- Polynucleotide delivery & targeting @ Radboudumc
- Oncology & Tissue-engineering
Open popup about Silvy van Tuijl
Silvy van Tuijl
Chief of Staff- 25+ yrs of experience
- Facilities, HR, Legal
More information
Chief of Staff
Silvy van Tuijl
Silvy is a Life Science Professional, with more than 25 years under her belt in diverse roles from Research analist at Sanquin to COO and now CSO (Chief of Staff) at RIBOPRO, bringing in tons of experience and energy to manage our facilities, 3rd party contractors and HR.
Under her guidance, the RIBOPRO team is rapidly growing, while developing a strong research-minded, cooperative company culture, with plenty of opportunity for enjoyment.
Silvy previously worked on:
- Daily management of a Biotech company
- Drug-development for age-related diseases
- Research on blood (factors)
Open popup about Yvette Zimmerman
Yvette Zimmerman
Chief Operating Officer- 25+ yrs of experience
- GMP & Quality
More information
Chief Operating Officer
Yvette Zimmerman
Yvette is a Drug Development Professional, experienced in global drug development in the pharmaceuticals industry for more than 25 years, in the field of Oncology, Women’s Health, Immunotherapy and Rheumatology.
She currently serves as the COO at RIBOPRO, with a particular focus on (setting up) GMP-operations, further building RIBOPRO’s Quality department, bolstering the R&D-grade production with lessons from the GMP, and setting-up consultancy services that help make a smooth transition from R&D to GMP.
Yvette has previously worked on:
- Pharmaceutical development in Women’s Health and Oncology
- Management of a Biotech company
- Out-licensing of assets
Open popup about Marc Penders
Marc Penders
Head of Innovation- 4+ yrs of experience
- R&D-grade mfg.
More information
Head of Innovation
Marc Penders
Marc is a driven professional, trained in the latest biotechnology and nanotechnology techniques. He applies this formal knowledge with a talent for automation, systems engineering and creative solutions to build robust, economical and high-performing (mRNA) production systems. As Head of Innovation, he makes it his personal mission to deliver the highest quality, on time.
Marc has previously worked on:
- Founding ChemNote, a start-up for specialty notebooks for chemistry
- QC-assays of LNPs and the lipids therein
- mRNA manufacturing
Synergistic value creation
Our partners
To offer our customers the best service possible, we collaborate with the best.
Advanced CDMO services for nanomedicines
Ardena
Ardena is an integrated service CDMO, assisting biopharma companies with services spanning the full development life cycle. The company offers a comprehensive ‘Make, Analyze, File’ model from drug substance and drug product manufacturing and bioanalytical services through to regulatory dossier development.
With a strong reputation for quality and a flexible service delivery model, Ardena caters to a highly diversified base of over 500 customers throughout Europe, the US, Japan and Korea. A high science approach and broad drug development toolkit differentiate Ardena from peers as a comprehensive multi-service pan-European platform.
We work together on:
- RIBOPRO provides advanced mRNA and LNP technologies to Ardena’s customers
- Ardena support GMP development and regulatory approval of LNP formulations to RiboPro’s customers
- Together, we provide an End-to-End solution for RNA therapy pioneers
Interested? Contact our BD-team via our dedicated contact page
RNA Readiness and Response
Wellcome Leap
The Wellcome Leap Health Breakthrough Network (HBNet) is the largest, most rapidly ‘activatable’ health research network in the world. With more than 100 world-class institutions, non-profits and commercial entities representing a network of over 1,000,000 scientists and engineers across six continents, they are able to increase speed and collaboration, reducing barriers to breakthroughs in human health.
We work together on:
- Changing the dynamics and costs of development and production
- Providing access to cGMP-formulated RNA
- Producing at speeds & quantities sufficient for emergency situations
Targeted mRNA therapeutics
Mercurna
Mercurna is a Netherlands-based biotechnology company working on targeted mRNA therapeutics, with candidates for chronic kidney disease (CKD), eye disease, bone-marrow disease, and skin disease in preclinical development. Their most advanced program uses an unique kidney-targeting peptide (glomerulus targeting) with exceptional specificity, targeting a previously unknown receptor.
We work together on:
- RiboPro supplies LNP & mRNA technologies to Mercurna
- RiboPro manufactures mRNA & LNP for Mercurna
- Mercurna provides specialized assays & targeting technology
GMP-manufacturing sites
Medace
Medace is a Maastricht, the Netherlands, based service provider who helps companies like RIBOPRO start GMP-manufacturing. Medace provides services related to setting up a QMS, provides personnel for QA and manufacturing tasks if needed, takes care of warehousing and offers GMP-compliant cleanrooms (grade A, B and C) for rent.
We work together on:
- RiboPro rents GMP-compliant cleanrooms (grade A & C)
- Medace provides GMP-compliant warehousing
- Medace provides support in setting up RIBOPRO’s QMS
From molecule to patient
Radboudumc
The Radboudumc is based in Nijmegen, the Netherlands, and besides its clinical practises houses more than 45 research departments, of which multiple now use RIBOPRO mRNA for research and therapy development. To ensure commercial viability, Radboudumc and RIBOPRO entered a license agreement focussed that provides a framework for continuous access to RIBOPRO’s patented mRNA technologies.
We work together on (among others):
- mRNA-supported CAR-T therapy
- Kidney disease
- LNP technologies
Partner with Professionals
Partnering with RIBOPRO
Partnering with RIBOPRO, as opposed to te more straight-forward customer-manufacturer relationship that we have with hundreds of customers, provides access to benefits such as priority manufacturing, extra financial/legal/product options, and contract research/co-development projects.
We like to work together on:
- mRNA manufacturing (also saRNA, circRNA and next-gen long RNA)
- LNP formulation
- Enzyme development
- Equipment development
Interested? Contact our BD-team via our dedicated contact page
For investors
To accelerate the growth of RIBOPRO, we are currently working on a Series A investment round. With this round, we aim to become a house-hold name in the mRNA field and expand our technology leadership position. We prefer to build a syndicate with both industry knowledge and follow-up investment capabilities represented.
Real-world evidence
What our customers say
"The staff at RiboPro have been very friendly and helpful throughout the ordering process."
Ben Wylie
"High quality reagents, clear communication and overall great service."
Joy Seiler
“RiboPro offers not only high-quality mRNA but also very helpful and fast support on all matters concerning mRNA.”
Jana Schembera
Researcher
“Good service paired with quick delivery and competitive pricing. Quality of delivered material was also very good. I can recommend RiboPro as a supplier of mRNA material.”
Arturs Aksjonovs
“RiboPro provided both the expert support and synthesized the high-quality mRNA to make our first gene manipulation experiments a resounding success. Furthermore, RiboPro was able to provide the mRNA constructs at an inordinate speed.”
Aviad Pato
Head of research at Gamida Cell
“Initially my results with mRNA were suboptimal, however with the support and dedication from the professionals at RiboPro, I was able to further optimize my experiments in such a way that my experiments turned out more successful.”
Jitske Jansen
Post-doc researcher Radboudumc